These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 12141956)

  • 1. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition in the treatment of cancer.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
    Paoluzzi L; O'Connor OA
    BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
    Tobinai K
    Int J Clin Oncol; 2007 Oct; 12(5):318-26. PubMed ID: 17929113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of bortezomib in the treatment of multiple myeloma.
    Cavo M
    Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
    Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition in hematologic malignancies.
    Richardson PG; Hideshima T; Mitsiades C; Anderson K
    Ann Med; 2004; 36(4):304-14. PubMed ID: 15224657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
    O'Connor OA
    Curr Treat Options Oncol; 2004 Aug; 5(4):269-81. PubMed ID: 15233904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic malignancies: new developments and future treatments.
    Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proteasome inhibitors].
    Alexandre J
    Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
    Koprivnikar JL; Cheson BD
    Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.